CompletedPhase 3NCT03771326
KP-10 and Insulin Secretion in Men
Quaid-e-Azam Universityn = 1429 Oct 2013 to 10 Jan 2014
Kisspeptin Action on Insulin in Healthy Normal Men · Kisspeptin Action on Insulin in Obese Diabetic Men
Kisspeptin-10 / Studies
Natural fragment · 10 amino acids · 1,302.4 Da
Kisspeptin-10 studies and research data
PepBank has 348 kisspeptin-10 studies with results. 273 of them gave kisspeptin-10, with 1,457 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 1,457 results and 420 papers. Newer studies from Europe PMC
Results in people
76
5% of 1,457 results
Results in animals
821
56% of 1,457 results
Results in lab cells
550
38% of 1,457 results
From computer models
10
under 1% of 1,457 results
The molecule
Kisspeptin-10 identity
Identifiers, parent molecule, targets and development stage, from curated data.
Kisspeptin-10 is the C-terminal decapeptide of human kisspeptin-54 (KISS1 precursor residues 112-121), H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. UniProt annotates this region as essential for receptor binding and activation, and it is an agonist of the kisspeptin receptor KISS1R (GPR54). It is used as a research tool in human reproductive and metabolic physiology studies and has no FDA or EMA approval.
- Kind
- Natural fragment · 10 residues
- Identifiers
- UniProtQ15726 (opens in a new tab)ChEMBLCHEMBL376756 (opens in a new tab)PubChem CID25240297 (opens in a new tab)UNIIFS1N52VS3S (opens in a new tab)CAS374675-21-5PDB8ZJD (opens in a new tab)
- Parent
- Fragment of Kisspeptin-54 (metastin) · residues 112-121UniProt Q15726 peptide features: Metastin 68-121 and Kisspeptin-10 112-121, both ending in Phe121 amide. PubChem and GSRS synonym 'Metastin 45-54'.
- Development
- Phase 2No company development program found. ClinicalTrials.gov labels three small academic studies 'Phase 3' (NCT03315325, NCT03771326, NCT03286517; 14-30 participants; primary purpose basic science; Pakistan); ChEMBL max_phase 3.0 comes from NCT03315325. Treatment-purpose studies reach Phase 2 (NCT04648969, completed, 18 participants; NCT07224438, recruiting, 20 planned; both kisspeptin 112-121, sponsor Stephanie B. Seminara, Boston). 'phase_2' is used here because the treatment-purpose studies are phase 2; the three registry-labelled phase 3 studies are small basic-science studies (see verification.unresolved). Source (opens in a new tab)
Targets
| Target | Action | Evidence |
|---|---|---|
| KiSS-1 receptorKISS1RQ969F8 (opens in a new tab) | Agonist | primary literatureSource (opens in a new tab) |
Sequence and structure
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence
10 amino acids · 1 modification
H-
Residues 1 to 10:
YNWNSFGLRF
Alignment to Kisspeptin-54 (metastin)
Calculated from the two sequences. Curated notes are shown as given.
10 of 10 aligned residues identical (100%) · 1 modified residue · Kisspeptin-54 (metastin) 45–54
- Top row: Kisspeptin-54 (metastin) (parent)
- Bottom row: Kisspeptin-10
YNWNSF
GLR
- Same as parent
- Substituted
- Non-canonical or D-form
- Added
- Gap
- Modified side chain or end
- Parent context
Differences from the parent
- 1Parent 54 · analog 10Phe, modified · C-terminal amideC-terminal phenylalaninamide (RF-amide). UniProt Q15726: 'Phenylalanine amide' at 121.
Basis: UniProt Q15726 peptide features: Metastin 68-121 and Kisspeptin-10 112-121, both ending in Phe121 amide. PubChem and GSRS synonym 'Metastin 45-54'.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
Properties
From identity sources
- Formula
- C63H83N17O14
- Molecular weight
- 1,302.4 g/mol
- Monoisotopic mass
- 1,301.6305 Da
- PubChem CID 25240297(opens in a new tab)retrieved 2026-10-08
- ChEMBL CHEMBL376756(opens in a new tab)retrieved 2026-10-08
- UniProt Q15726(opens in a new tab)retrieved 2026-10-08
- GSRS UNII FS1N52VS3S(opens in a new tab)retrieved 2026-10-08
Calculated from the sequence
- Average mass
- 1,302.46 Da
- Sum of ExPASy residue masses + water + C-amide · ExPASy Compute pI/Mw; FindMod
- Monoisotopic mass
- 1,301.6305 Da
- Sum of ExPASy residue masses + water + C-amide · ExPASy FindMod
- Isoelectric point (pI)
- 11.31
- pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
- Net charge at pH 7.4
- 1.94
- Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
- GRAVY (hydropathy)
- −0.550
- Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982
- Negative: hydrophilic on average.
- Extinction coefficient, 280 nm (Cys reduced)
- 6,990 M⁻¹ cm⁻¹
- 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
- Instability index
- 30.23
- Dipeptide instability weights (DIWV) · Guruprasad et al. 1990
- 40 or below: classed as stable (ExPASy).
- Aliphatic index
- 39.0
- Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
- Boman index
- 1.76 kcal/mol
- Mean solubility value (negated) · Boman 2003
- 2.48 or below: lower protein-binding potential (Boman).
- Hydrophobic moment (μH)
- Not calculated
- The sequence is too short for this method.
- pI with each pKa set
- EMBOSS 11.31Bjellqvist (ExPASy) 11.00IPC peptide 11.35IPC protein 11.35
- Defined and validated for proteins; use with care for short peptides.
- Assumes an ideal alpha helix. Many short peptides are not helical.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
Net charge by pH
pI 11.31 · Net charge at pH 7.4: 1.94
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set, C-amide. Calculated, not measured.
Show as table
| pH | Net charge |
|---|---|
| 0 | 2.00 |
| 1 | 2.00 |
| 2 | 2.00 |
| 3 | 2.00 |
| 4 | 2.00 |
| 5 | 2.00 |
| 6 | 2.00 |
| 7 | 1.97 |
| 8 | 1.79 |
| 9 | 1.21 |
| 10 | 0.59 |
| 11 | 0.09 |
| 12 | −0.23 |
| 13 | −0.76 |
| 14 | −0.97 |
Composition
- Hydrophobic10% (1)L
- Aromatic40% (4)F W Y
- Positive10% (1)R
- Polar30% (3)N S
- Special10% (1)G
10 residues. Each residue counts in one class; F and W count as aromatic.
A Ala0 · 0%
I Ile0 · 0%
L Leu1 · 10%
M Met0 · 0%
V Val0 · 0%
F Phe2 · 20%
W Trp1 · 10%
Y Tyr1 · 10%
H His0 · 0%
K Lys0 · 0%
R Arg1 · 10%
D Asp0 · 0%
E Glu0 · 0%
N Asn2 · 20%
Q Gln0 · 0%
S Ser1 · 10%
T Thr0 · 0%
C Cys0 · 0%
G Gly1 · 10%
P Pro0 · 0%
3D structure
ExperimentalPDB 8ZJD
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from RCSB PDB.
2D structure
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 25240297(opens in a new tab)
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)NResults by area
What the studies measured
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
Trials and papers
Newer studies
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Status and safety
Data